Fibrocell Resubmission Email, January 5, 2011

From: Thomas, John
Sent: Wednesday, January 05, 2011 11:21 AM
To: Tull, Lori; Fink, Donald; Haudenschild, Changting; Hoque, Atm S.; Lee, Shiowjen; Lim, Agnes; Melhem, Randa; Ou, Alan C.; Stockbridge, Lisa L; Wang, Gang; White, Janet; Zhu, Yao-Yao; Zinderman, Craig E; Buckler, Aileen
  Cc: Wonnacott, Keith; Simek, Stephanie; Puri, Raj K. (FDA/CBER); Benton, Kimberly; Witten, Celia (CBER); Bryan, Wilson; Schneider, Bruce; Serabian, Mercedes; Wise, Robert

  Subject: RE: Fibrocell BLA STN 125348 Resubmission

Lori,

The CMC portion of the resubmission is complete.

Also, can you set up a review team meeting so we can discuss timelines etc for completing the review of this resubmission?

Thanks,
  Terrig

--------------------------------------------------------------------------------
  From: Tull, Lori
  Sent: Wednesday, December 22, 2010 8:55 AM
  To: Thomas, John; Fink, Donald; Haudenschild, Changting; Hoque, Atm S.; Lee, Shiowjen; Lim, Agnes; Melhem, Randa; Ou, Alan C.; Stockbridge, Lisa L; Wang, Gang; White, Janet; Zhu, Yao-Yao; Zinderman, Craig E
  Cc: Wonnacott, Keith; Simek, Stephanie; Puri, Raj K. (FDA/CBER); Benton, Kimberly; Witten, Celia (CBER); Bryan, Wilson; Schneider, Bruce; Serabian, Mercedes; Syin, Chiang; Waites, Nancy; Norwood, Laurie; Crim, James; Wise, Robert; Holobaugh, Patricia  

Subject: Fibrocell BLA STN 125348 Resubmission

Hello all,

We have received Fibrocell's resubmission for their BLA 125348.  The final study report for the histology study is in the EDR (amendment 34).  Amendments 28, 30, and 33 are also in the EDR and contain additional responses to the CR letter.

Please let me know by 1/7/11 if you agree that the resubmission is complete.  If so, this will be a class 2 resubmission with a due date of June 22, 2011.  I need to send a confirmation letter to the company no later than 1/11/11.

Thanks,
  Lori

Lori A. Tull, RAC
  Regulatory Project Manager
  Office of Cellular, Tissue, and Gene Therapies
  Center for Biologics Evaluation and Research
  (301) 827-5359

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.